A Chlamydia trachomatis VD1-MOMP vaccine elicits cross-neutralizing and protective antibodies against C/C-related complex serovars

Abstract Ocular and urogenital infections with Chlamydia trachomatis (C.t.) are caused by a range of different serovars. The first C.t. vaccine in clinical development (CTH522/CAF®01) induced neutralizing antibodies directed to the variable domain 4 (VD4) region of major outer membrane protein (MOMP...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Anja Weinreich Olsen, Ida Rosenkrands, Martin J. Holland, Peter Andersen, Frank Follmann
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Immunologic diseases. Allergy RC581-607 Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/6344e9e5dba04b32bbb648fc6b896476
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:6344e9e5dba04b32bbb648fc6b896476
record_format	dspace
spelling	oai:doaj.org-article:6344e9e5dba04b32bbb648fc6b8964762021-12-02T13:39:34ZA Chlamydia trachomatis VD1-MOMP vaccine elicits cross-neutralizing and protective antibodies against C/C-related complex serovars10.1038/s41541-021-00312-92059-0105https://doaj.org/article/6344e9e5dba04b32bbb648fc6b8964762021-04-01T00:00:00Zhttps://doi.org/10.1038/s41541-021-00312-9https://doaj.org/toc/2059-0105Abstract Ocular and urogenital infections with Chlamydia trachomatis (C.t.) are caused by a range of different serovars. The first C.t. vaccine in clinical development (CTH522/CAF®01) induced neutralizing antibodies directed to the variable domain 4 (VD4) region of major outer membrane protein (MOMP), covering predominantly B and intermediate groups of serovars. The VD1 region of MOMP contains neutralizing B-cell epitopes targeting serovars of the C and C-related complex. Using an immuno-repeat strategy, we extended the VD1 region of SvA and SvJ to include surrounding conserved segments, extVD1A and extVD1J, and repeated this region four times. The extVD1A4 was most immunogenic with broad cross-surface and neutralizing reactivity against representative members of the C and C-related complex serovars. Importantly, in vitro results for extVD1A4 translated into in vivo biological effects, demonstrated by in vivo neutralization of SvA and protection/cross-protection against intravaginal challenge with both SvA and the heterologous SvIa strain.Anja Weinreich OlsenIda RosenkrandsMartin J. HollandPeter AndersenFrank FollmannNature PortfolioarticleImmunologic diseases. AllergyRC581-607Neoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENnpj Vaccines, Vol 6, Iss 1, Pp 1-11 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Immunologic diseases. Allergy RC581-607 Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	Immunologic diseases. Allergy RC581-607 Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Anja Weinreich Olsen Ida Rosenkrands Martin J. Holland Peter Andersen Frank Follmann A Chlamydia trachomatis VD1-MOMP vaccine elicits cross-neutralizing and protective antibodies against C/C-related complex serovars
description	Abstract Ocular and urogenital infections with Chlamydia trachomatis (C.t.) are caused by a range of different serovars. The first C.t. vaccine in clinical development (CTH522/CAF®01) induced neutralizing antibodies directed to the variable domain 4 (VD4) region of major outer membrane protein (MOMP), covering predominantly B and intermediate groups of serovars. The VD1 region of MOMP contains neutralizing B-cell epitopes targeting serovars of the C and C-related complex. Using an immuno-repeat strategy, we extended the VD1 region of SvA and SvJ to include surrounding conserved segments, extVD1A and extVD1J, and repeated this region four times. The extVD1A4 was most immunogenic with broad cross-surface and neutralizing reactivity against representative members of the C and C-related complex serovars. Importantly, in vitro results for extVD1A4 translated into in vivo biological effects, demonstrated by in vivo neutralization of SvA and protection/cross-protection against intravaginal challenge with both SvA and the heterologous SvIa strain.
format	article
author	Anja Weinreich Olsen Ida Rosenkrands Martin J. Holland Peter Andersen Frank Follmann
author_facet	Anja Weinreich Olsen Ida Rosenkrands Martin J. Holland Peter Andersen Frank Follmann
author_sort	Anja Weinreich Olsen
title	A Chlamydia trachomatis VD1-MOMP vaccine elicits cross-neutralizing and protective antibodies against C/C-related complex serovars
title_short	A Chlamydia trachomatis VD1-MOMP vaccine elicits cross-neutralizing and protective antibodies against C/C-related complex serovars
title_full	A Chlamydia trachomatis VD1-MOMP vaccine elicits cross-neutralizing and protective antibodies against C/C-related complex serovars
title_fullStr	A Chlamydia trachomatis VD1-MOMP vaccine elicits cross-neutralizing and protective antibodies against C/C-related complex serovars
title_full_unstemmed	A Chlamydia trachomatis VD1-MOMP vaccine elicits cross-neutralizing and protective antibodies against C/C-related complex serovars
title_sort	chlamydia trachomatis vd1-momp vaccine elicits cross-neutralizing and protective antibodies against c/c-related complex serovars
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/6344e9e5dba04b32bbb648fc6b896476
work_keys_str_mv	AT anjaweinreicholsen achlamydiatrachomatisvd1mompvaccineelicitscrossneutralizingandprotectiveantibodiesagainstccrelatedcomplexserovars AT idarosenkrands achlamydiatrachomatisvd1mompvaccineelicitscrossneutralizingandprotectiveantibodiesagainstccrelatedcomplexserovars AT martinjholland achlamydiatrachomatisvd1mompvaccineelicitscrossneutralizingandprotectiveantibodiesagainstccrelatedcomplexserovars AT peterandersen achlamydiatrachomatisvd1mompvaccineelicitscrossneutralizingandprotectiveantibodiesagainstccrelatedcomplexserovars AT frankfollmann achlamydiatrachomatisvd1mompvaccineelicitscrossneutralizingandprotectiveantibodiesagainstccrelatedcomplexserovars AT anjaweinreicholsen chlamydiatrachomatisvd1mompvaccineelicitscrossneutralizingandprotectiveantibodiesagainstccrelatedcomplexserovars AT idarosenkrands chlamydiatrachomatisvd1mompvaccineelicitscrossneutralizingandprotectiveantibodiesagainstccrelatedcomplexserovars AT martinjholland chlamydiatrachomatisvd1mompvaccineelicitscrossneutralizingandprotectiveantibodiesagainstccrelatedcomplexserovars AT peterandersen chlamydiatrachomatisvd1mompvaccineelicitscrossneutralizingandprotectiveantibodiesagainstccrelatedcomplexserovars AT frankfollmann chlamydiatrachomatisvd1mompvaccineelicitscrossneutralizingandprotectiveantibodiesagainstccrelatedcomplexserovars
_version_	1718392617571450880

A Chlamydia trachomatis VD1-MOMP vaccine elicits cross-neutralizing and protective antibodies against C/C-related complex serovars

Ejemplares similares